Prosecution Insights
Last updated: November 12, 2026

Corcept Therapeutics Incorporated

Technology area: Biotechnology & Pharmaceuticals

8 pending office actions • 5 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days

Analysis

Corcept Therapeutics Incorporated has 8 pending office actions in Biotechnology & Pharmaceuticals. Those actions are spread among 8 distinct examiners and 5 distinct art units. The examiner count matches the action count, while the lower art unit count indicates that some art units handle matters assigned to different examiners.

TRAN, ERIC is the busiest examiner, with 1 pending matter. No examiner carries more than that figure in the supplied data, so prosecution management should emphasize consistent claim support and issue tracking across the separate examiner assignments.

The distribution across 5 art units creates a coordination need for counsel. Responses can be organized around recurring technology and claim themes, while still preserving examiner-specific arguments where the records require them.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

8
Total Pending OAs
8
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (12%)
2
Medium (25%)
5
Easy (62%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only2 (25%)
Double-patenting only3 (38%)
Double-patenting + other2 (25%)
Multi-statute (no §101)1 (12%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

8
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
TRAN, ERIC 1 69.7% +19.4%
SEAMAN, D MARGARET M 1 76.7% +8.0%
DAHLIN, HEATHER RAQUEL 1 41.9% +46.0%
HEASLEY, MEGHAN CHRISTINE 1 75.7% +36.8%
WILLIS, DOUGLAS M 1 82.4% +19.8%
MARTIN, KEVIN STEPHEN 1 77.0% +20.7%
MCDOWELL, BRIAN E 1 74.0% +31.3%
RODRIGUEZ, RAYNA B 1 33.4% +19.3%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18676126 SULFONE METHOD OF PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS WILLIS, DOUGLAS M —

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18779659 Treatment of Hypercoagulopathy in Cushing's Syndrome by Administration of Glucocorticoid Receptor Modulators DAHLIN, HEATHER RAQUEL —

Interview Candidates (7)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
18920639 METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS TRAN, ERIC —
18779659 Treatment of Hypercoagulopathy in Cushing's Syndrome by Administration of Glucocorticoid Receptor Modulators DAHLIN, HEATHER RAQUEL —
18764781 BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS HEASLEY, MEGHAN CHRISTINE —
18676126 SULFONE METHOD OF PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS WILLIS, DOUGLAS M —
18670160 METHODS FOR TREATING ADRENAL GLAND TUMORS MARTIN, KEVIN STEPHEN —
18584163 METHODS OF PREPARING INTERMEDIATES OF HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS MCDOWELL, BRIAN E —
18444342 Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient RODRIGUEZ, RAYNA B —

Top Art Units

Art UnitApps
1624 3
1629 2
1625 1
1626 1
1628 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18920639 METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS TRAN, ERIC 1629 DP Non-Final OA — Pending Oct 18, 2024
18908611 POLYMORPHS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS SEAMAN, D MARGARET M 1625 DP Non-Final OA — Pending Oct 07, 2024
18779659 Treatment of Hypercoagulopathy in Cushing's Syndrome by Administration of Glucocorticoid Receptor Modulators DAHLIN, HEATHER RAQUEL 1629 §102§103§112Other Non-Final OA — Pending Jul 22, 2024
18764781 BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS HEASLEY, MEGHAN CHRISTINE 1626 DP Non-Final OA — Pending Jul 05, 2024
18676126 SULFONE METHOD OF PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS WILLIS, DOUGLAS M 1624 §112 Non-Final OA — Pending May 28, 2024
18670160 METHODS FOR TREATING ADRENAL GLAND TUMORS MARTIN, KEVIN STEPHEN 1624 §103§112DP Non-Final OA — Pending May 21, 2024
18584163 METHODS OF PREPARING INTERMEDIATES OF HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS MCDOWELL, BRIAN E 1624 §112 Non-Final OA — Pending Feb 22, 2024
18444342 Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient RODRIGUEZ, RAYNA B 1628 §102§103§112DP Non-Final OA — Pending Feb 16, 2024

Managing Corcept Therapeutics Incorporated's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Corcept Therapeutics Incorporated have?

Corcept Therapeutics Incorporated has 8 pending office actions as of November 2026, spread across 5 art units and 8 examiners.

Which USPTO examiner handles the most Corcept Therapeutics Incorporated applications?

Eric Tran has the most, with 1 of Corcept Therapeutics Incorporated's pending office actions.

What technology area are Corcept Therapeutics Incorporated's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month